0000950170-23-051733.txt : 20231003
0000950170-23-051733.hdr.sgml : 20231003
20231003192118
ACCESSION NUMBER: 0000950170-23-051733
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230929
FILED AS OF DATE: 20231003
DATE AS OF CHANGE: 20231003
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Aziz Kabeer
CENTRAL INDEX KEY: 0001914847
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41331
FILM NUMBER: 231306111
MAIL ADDRESS:
STREET 1: 376 MANHATTAN AVENUE APT. 3
CITY: BROOKLYN
STATE: NY
ZIP: 11211
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AN2 Therapeutics, Inc.
CENTRAL INDEX KEY: 0001880438
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 820606654
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1800 EL CAMINO REAL, SUITE D
CITY: MENLO PARK
STATE: CA
ZIP: 94027
BUSINESS PHONE: (650) 331-9090
MAIL ADDRESS:
STREET 1: 1800 EL CAMINO REAL, SUITE D
CITY: MENLO PARK
STATE: CA
ZIP: 94027
4
1
ownership.xml
4
X0508
4
2023-09-29
0001880438
AN2 Therapeutics, Inc.
ANTX
0001914847
Aziz Kabeer
C/O AN2 THERAPEUTICS, INC.
1800 EL CAMINO REAL, SUITE D
MENLO PARK
CA
94027
true
false
true
false
false
Common Stock
2023-09-29
4
S
false
83337
16.28
D
2086343
I
By Adjuvant Global Health Technology Fund, L.P.
Common Stock
2023-09-29
4
S
false
15764
16.28
D
394639
I
By Adjuvant Global Health Technology Fund DE, L.P.
Common Stock
2023-10-02
4
S
false
4770
16.07
D
2081573
I
By Adjuvant Global Health Technology Fund, L.P.
Common Stock
2023-10-02
4
S
false
902
16.07
D
393737
I
By Adjuvant Global Health Technology Fund DE, L.P.
The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022.
The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.95, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Shares held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.
Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.
The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.10, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
/s/ Kabeer Aziz
2023-10-03